BORMANN-KENNEDY BARBARA-JEAN ANNE 4

4 · Xeris Biopharma Holdings, Inc. · Filed Jun 9, 2022

Insider Transaction Report

Form 4
Period: 2022-06-08
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-06-08+25,00025,000 total
    Exercise: $2.10From: 2022-06-08Exp: 2032-06-08Common Stock (25,000 underlying)
  • Award

    Common Stock

    2022-06-08$2.10/sh+15,000$31,50015,000 total
Footnotes (2)
  • [F1]These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.
  • [F2]Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.

Documents

2 files
  • 4
    wf-form4_165480929594664.xmlPrimary

    FORM 4

  • EX-24

    BORMANN-KENNEDY, BARBARA JEAN ANNE POA